Satellos Bioscience Inc.(MSCL-TSXV/MSCLF-OTCQB)

Satellos Bioscience Inc.
200 Bay Street, Suite 2800
Toronto, ON M5J 2J1
Canada
Phone: (647) 660-1780
https://satellos.com/ 

Satellos Bioscience Inc. (“Satellos” or “the Company”) is a biotechnology company dedicated to developing life-changing medicines to treat degenerative muscle conditions. The Company’s scientists have discovered what could possibly be a previously unrecognized root cause of skeletal muscle degeneration, which may transform how muscle disorders are treated. Satellos’ scientific founder, Dr. Michael Rudnicki, is a thought leader who discovered and has shown how muscle stem cells regulate muscle repair and growth throughout life. He has demonstrated how defects in a process known as stem cell “polarity”, which controls how muscle stem cells divide to create muscle progenitor cells, lead to a failure of muscle regeneration in patients with Duchenne muscular dystrophy (DMD)—a rare genetic disorder of progressive muscular weakness that affects boys almost exclusively. As a result of this ongoing inability to produce sufficient numbers of new muscle cells, the muscles of individuals living with Duchenne are unable to keep up with and repair the continuous and accumulating damage to their muscles. Satellos is developing a small molecule oral therapeutic intended to correct muscle stem cell polarity and restore the body’s innate muscle repair and regeneration process. This unique therapeutic approach could prove to be a disease modifying treatment for patients with Duchenne as well as other muscular dystrophies. To expand its programs into other degenerative muscle conditions or disorders, Satellos has created MyoReGenX™, a proprietary discovery platform, which the Company utilizes to identify disease situations where deficits in muscle stem cell polarity and regeneration occur and are open to therapeutic treatment.

* The Corporate Snapshot was last updated on October 5, 2023.